A presentation on thimerosal, a mercury-based vaccine preservative, set to be delivered to the CDC’s advisory committee has come under scrutiny for referencing a non-existent study. The report, “Thimerosal as a Vaccine Preservative,” authored by Lyn Redwood—former leader of the anti-vaccine group Children’s Health Defense—cited a 2008 study allegedly co-authored by UC Davis Professor Emeritus Robert Berman. However, Berman confirmed that such a study was never conducted by him and said the cited findings misrepresented his actual research published in Toxicological Sciences.
The erroneous citation was first reported by Reuters, prompting the CDC to upload a revised version of Redwood’s presentation, removing the disputed slide. The controversy has intensified after Health Secretary Robert F. Kennedy Jr. recently replaced the CDC’s entire 17-member vaccine panel with eight new members, half of whom are known vaccine skeptics.
Both Republican Senator Bill Cassidy and Democratic Senator Patty Murray have urged postponement of the June 25–26 meeting, citing the panel’s lack of vetting and the absence of a CDC director. Redwood’s presentation contrasts with a separate CDC staff report reaffirming that thimerosal-containing vaccines do not cause autism or other neurodevelopmental issues.
According to CDC data, 96% of flu vaccines administered during the 2024–25 season were thimerosal-free, and only 0.3% of flu vaccines given to pregnant women contained the preservative. Kennedy, a long-time critic of vaccine safety, has previously claimed thimerosal causes brain damage—claims consistently debunked by scientific research.
The thimerosal debate highlights rising tensions around vaccine policy and misinformation, especially as newly appointed CDC advisors consider whether to recommend thimerosal-free vaccines for all pregnant women and children. Redwood has not yet responded to requests for comment.


NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
Tabletop particle accelerator could transform medicine and materials science
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
Taiwan Confident in Strong U.S. Relations Ahead of Trump-Xi China Summit
Trump Administration Seeks Court Pause to Reinstate 10% Global Tariffs
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
US Sanctions Target Iran Oil Network Supplying China Ahead of Trump-Xi Talks
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone
Trump Weighs Renewed Military Action Against Iran Amid Strait of Hormuz Crisis
Rubio Discusses Iran Crisis and Strait of Hormuz Disruptions With UK and Australia
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 



